The graph belows shows the FinnGen expenditure distribution for the first three years of the study. The data is based on March 2020 situation / budget forecast. Half of the funding has been used to cover costs related to biobank sample collection and handling. The next largest items of expenditure are data processing & analyses activities (mainly personnel costs) and genotyping with ThermoFisher's array. In addition, significant investments to IT and data security have been made.
The total budget exceeds 80 M €. Approximately 20 M € comes from Business Finland and the rest from the international pharmaceutical industry partners: AbbVie, AstraZeneca, Biogen, Celgene/Bristol-Myers Scibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.